Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee,The Lancet Oncology

当前位置： X-MOL 学术 › Lancet Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-05-28 , DOI: 10.1016/s1470-2045(24)00094-9
Yi Lin ₁ , Lugui Qiu ₂ , Saad Usmani ₃ , Chng Wee Joo ₄ , Luciano Costa ₅ , Benjamin Derman ₆ , Juan Du ₇ , Hermann Einsele ₈ , Carlos Fernandez de Larrea ₉ , Roman Hajek ₁₀ , P Joy Ho ₁₁ , Efstathios Kastritis ₁₂ , Joaquin Martinez-Lopez ₁₃ , Maria-Victoria Mateos ₁₄ , Joseph Mikhael ₁₅ , Philippe Moreau ₁₆ , Chandramouli Nagarajan ₁₇ , Ajay Nooka ₁₈ , Michael O'Dwyer ₁₉ , Fredrik Schjesvold ₂₀ , Surbhi Sidana ₂₁ , Niels Wcj van de Donk ₂₂ , Katja Weisel ₂₃ , Sonja Zweegman ₂₂ , Noopur Raje ₂₄ , Paula Rodriguez Otero ₂₅ , Larry D Anderson ₂₆ , Shaji Kumar ₁ , Tom Martin ₂₇ ,

Affiliation

Department of Hematology, Mayo Clinic, Rochester, MN, USA.
National Clinical Research Center for Blood Diseases and State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Pekin Union Medical College, Tianjin, China.
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Medical Oncology, National University Cancer Institute, Singapore.
Department of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Hematology and Oncology, University of Chicago, Chicago, IL, USA.
Department of Hematology, Myeloma and Lymphoma Center, Shanghai Changzheng Hospital, Navy Medical University, Shanghai, China.
Department of Internal Medicine II, University Hospital, Wurzburg, Germany.
Department of Hematology, Hospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic; Department of Hematooncology, Faculty of Medicine, University Ostrava, Ostrava, Czech Republic.
Institute of Hematology, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia.
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Hospital Universitario 12 de Octubre, Department of Medicine, Complutense University, CNIO, Madrid, Spain.
Hospital Universitario de Salamanca, Salamanca, Spain.
Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA.
Department of Hematology, University Hospital of Nantes, Nantes, France.
Department of Haematology, Singapore General Hospital, Singapore.
Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Department of Medicine and Department of Haematology, National University of Ireland, Galway, Ireland.
Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway.
School of Medicine, Stanford University, San Francisco, CA, USA.
Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands.
Department of Oncology, Hematology and Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Medicine, Harvard University, Cambridge, MA, USA.
Department of Hematology, Cancer Center Clinica Universidad de Navarra, Pamplona, Navarra, Spain.
Simmons Comprehensive Cancer Center, Dallas, TX, USA; University of Texas Southwestern Medical Center, Dallas, TX, USA.
Department of Hematology, University of California, San Francisco, CA, USA.

Chimeric antigen receptor (CAR) T-cell therapy has shown promise in patients with late-line refractory multiple myeloma, with response rates ranging from 73 to 98%. To date, three products have been approved: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which are approved by the US Food and Drug Administration, the European Medicines Agency, Health Canada (ide-cel only), and Brazil ANVISA (cilta-cel only); and equecabtagene autoleucel (eque-cel), which was approved by the Chinese National Medical Products Administration. CAR T-cell therapy is different from previous anti-myeloma therapeutics with unique toxic effects that require distinct mitigation strategies. Thus, a panel of experts from the International Myeloma Working Group was assembled to provide guidance for clinical use of CAR T-cell therapy in myeloma. This consensus opinion is from experts in the field of haematopoietic cell transplantation, cell therapy, and multiple myeloma therapeutics.

更新日期：2024-05-28

点击分享查看原文

点击收藏

阅读更多本刊新发论文